NCODA developed Treatment Support Kits (TSKs) to provide patients and caregivers with resources that make sense for adverse event (AE) management when taking oral anti-cancer medications.

**Origins**
- A beta test at 24 community and health system cancer centers was conducted in 2018-2019 to determine viability of TSKs.
- A total of 240 capecitabine kits were distributed, and patients & HCPs were surveyed.

**Beta Test Results**
- 85% of patients stated they needed the kit.
- 90% of patients rated the kit as high quality.
- 100% of providers rated the kit as useful.

**Kits Available**
- Abemaciclib
- Abiraterone
- Cabozantinib
- Capecitabine
- Neratinib
- Pacritinib
- Regorafenib
- Temozolomide
- Tivozanib

**Leadership**
A committee of clinical experts determines what educational and OTC products are included in each TSK.

**Benefits**
- Curated content and products determined by clinical experts.
- Easy to read educational material.
- Avoid manufacturer branding hurdles in clinics.
- Kit options available for generic oral anticancer medications.

**Learn More & Order Kits**
TSKs have been manufactured for the following companies:

- AVEO Oncology
- Bayer
- CTI
- EXELIXIS
- Karyopharm Therapeutics
- Lilly
- ONCOLOGY
- PharMerica
- TAIHO ONCOLOGY
- Takeda
- ONCOLOGY